EzatiostatHydrochloride
CAS: 286942-97-0
Rif. 3D-FE152274
| 2mg | Fuori produzione | ||
| 5mg | Fuori produzione | ||
| 10mg | Fuori produzione | ||
| 25mg | Fuori produzione | ||
| 50mg | Fuori produzione |
Informazioni sul prodotto
- L-gamma-Glutamyl-S-(phenylmethyl)-L-cysteinyl-2-phenylglycine diethyl ester monohydrochloride
Ezatiostat is a small molecule that inhibits the methyltransferase activity of DNA-dependent RNA polymerase. It is being developed as a specific treatment for polymorphic and monomorphic hematologic malignancies, such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), and has shown promising results in preclinical studies. Ezatiostat selectively inhibits the enzyme that regulates the mitochondrial membrane potential, which can lead to cell death by apoptosis. In vitro experiments have demonstrated that ezatiostat can inhibit colony-stimulating factor (CSF) production by inhibiting CSF-1 receptor expression on hematopoietic stem cells. This drug also has been shown to be toxic to cells with mutations in the MCL-1 protein, which may be due to its ability to bind this protein.
